Cytochrome P450 Enzymes as Drug Targets in Human Disease

被引：16

作者：

Guengerich, F. Peter ^{[1
,2
]}

机构：

[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, 638B Robinson Res Bldg, 2200 Pierce Ave, Nashville, TN 37232 USA

来源：

DRUG METABOLISM AND DISPOSITION | 2024年 / 52卷 / 06期

基金：

美国国家卫生研究院;

关键词：

LANOSTEROL 14-ALPHA-DEMETHYLASE CYP51; SYNTHASE CYP11B2 INHIBITORS; CUSHINGS-SYNDROME; DISCOVERY; ANTIFUNGAL; METABOLISM; MECHANISM; SCH-56592; KNOCKOUT; MOLECULE;

D O I：

10.1124/dmd.123.001431

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Although the mention of cytochrome P450 (P450) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential, but in certain disease states, it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in use, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e.g., P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1.

引用

收藏

页码：493 / 497

页数：5

相关论文

共 55 条

[31] First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis [J].

Karimaa, Mari ;

Riikonen, Reetta ;

Kettunen, Henna ;

Taavitsainen, Paivi ;

Ramela, Meri ;

Chrusciel, Marcin ;

Karlsson, Stefan ;

Rummakko, Petteri ;

Simola, Outi ;

Wohlfahrt, Gerd ;

Hakulinen, Pasi ;

Vuorela, Annamari ;

Joensuu, Heikki ;

Utriainen, Tapio ;

Fizazi, Karim ;

Oksala, Riikka .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) :1765-1776

[32] Mouse Knockout of the Cholesterogenic Cytochrome P450 Lanosterol 14α-Demethylase (Cyp51) Resembles Antley-Bixler Syndrome [J].

Keber, Rok ;

Motaln, Helena ;

Wagner, Kay D. ;

Debeljak, Natasa ;

Rassoulzadegan, Minoo ;

Acimovic, Jure ;

Rozman, Damjana ;

Horvat, Simon .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (33) :29086-29097

[33]

King AN, 2010, ANTI-CANCER AGENT ME, V10, P213

[34] Nirmatrelvir Plus Ritonavir: First Approval [J].

Lamb, Yvette N. .

DRUGS, 2022, 82 (05) :585-591

[35] Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms [J].

Lepesheva, Galina I. ;

Waterman, Michael R. .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2007, 1770 (03) :467-477

[36] CYP51 as drug targets for fungi and protozoan parasites: past, present and future [J].

Lepesheva, Galina I. ;

Friggeri, Laura ;

Waterman, Michael R. .

PARASITOLOGY, 2018, 145 (14) :1820-1836

[37] CYP51 from Trypanosoma brucei is obtusifoliol-specific [J].

Lepesheva, GI ;

Nes, WD ;

Zhou, WX ;

Hill, GC ;

Waterman, MR .

BIOCHEMISTRY, 2004, 43 (33) :10789-10799

[38] Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281 [J].

Liu, Jinghan ;

Offei, Samuel D. ;

Yoshimoto, Francis K. ;

Scott, Emily E. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (04)

[39] 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures [J].

Meguro, Masaki ;

Miyauchi, Satoru ;

Kanao, Yukiko ;

Naito, Satoru ;

Suzuki, Kanae ;

Inoue, Shinichi ;

Yamada, Keisuke ;

Homma, Tsuyoshi ;

Chiba, Kiyoshi ;

Nara, Futoshi ;

Furuzono, Shinji .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (09) :1902-1906

[40] The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders [J].

Miller, Walter L. ;

Auchus, Richard J. .

ENDOCRINE REVIEWS, 2011, 32 (01) :81-151

← 1 2 3 4 5 6 →